QUARK SIGNS RESEARCH PACT WITH SHIONOGI.Quark Biotech, Inc. (QBI QBI Queensland Brain Institute (Brisbane, Australia) QBI Quality Botanical Ingredients, Inc. QBI Quite Bloody Impossible QBI Quantile-Based Inspection Scheme QBI Qualified Best Images ), Pleasanton, Calif., has entered into a collaborative research and license agreement with Shionogi & Co. to discover, identify, and analyze genes associated with osteoarthritis osteoarthritis or osteoarthrosis or degenerative joint disease Most common joint disorder, afflicting over 80% of those who reach age 70. It does not involve excessive inflammation and may have no symptoms, especially at first. (OA). Under the terms of the agreement, QBI will use its proprietary technology to discover, identify and determine the function of OA-related genes. Shionogi will seek to develop and manufacture pharmaceutical and diagnostic candidates resulting from these genes. Shionogi will have exclusive marketing rights in the Far East; Shionogi and QBI will share co-marketing rights throughout the rest of the world. Osteoarthritis, also known as degenerative joint disease degenerative joint disease n. Abbr. DJD See osteoarthritis. degenerative joint disease Osteoarthritis, see there , is one of the most common types of arthritis. It is characterized by the disappearance of the joint's cartilage and the formation of osteophytes. According to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. the Arthritis Foundation, osteoarthritis affects an estimated 15.8 million people in America. Symptomatic treatments exist, but there is presently no curative therapy. Through this collaborative research agreement with QBI, Shionogi aims to develop pharmaceutical and diagnostic agents for osteoarthritis, and also expects to obtain significant knowledge and experience in genomic technology related to drug discovery research, such as disease-related gene searching and bioinformatics. Quark Biotech, Inc. is a privately-held genomics company engaged in pathology-specific gene discovery designed to identify, select and validate genes and gene products as diagnostics and drug candidates in virtually every disease category. QBI's integrated platform of complementary genomic and bioinformatic technologies focuses on those genes responsible for pathogenesis and distinguishes those which are well-suited for drug development. QBI recently signed research and licensing agreements with The New York Blood Center New York Blood Center bills itself as the "nation's largest, community-based, non-profit, independent blood center." Founded in 1964, it relies upon a staff of 2,000 volunteers and a much smaller permanent staff in order to supply over 200 hospitals in New York and New Jersey with , Fujisawa Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., and a second agreement with Sankyo Co., Ltd. As a result of QBI's collaborative research with the University of Illinois University of Illinois may refer to:
Effects of a proposed project on other parts of the firm. associated with cancer radiation therapy. Based in Pleasanton, Calif., QBI has research facilities in Israel, and conducts research in Chicago and the San Francisco Bay area “Bay Area” redirects here. For other uses, see Bay Area (disambiguation). The San Francisco Bay Area, colloquially known as the Bay Area or The Bay . For additional news and information, please visit the company at http://www.quarkbiotech.com. Shionogi & Co., Ltd, headquartered in Osaka, Japan, is one of the leading Japanese pharmaceutical companies. Actively involved in research and development, Shionogi's research strengths include infectious diseases, cardiovascular disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease , cancer and inflammation. Shionogi has a highly-trained sales promotion staff who enjoys the respect of Japanese doctors. Recently, Shionogi bolstered its manufacturing capabilities through the establishment of the Bushu Pharmaceuticals subsidiary. For more information, call 888-498-8933. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion